.Pharmacolibrary.Drugs.ATC.C.C09XA02

Information

Aliskiren is a direct renin inhibitor used primarily for the treatment of hypertension. It reduces plasma renin activity and lowers blood pressure. Aliskiren is approved for clinical use in several countries, though its usage may be limited due to safety concerns in some specific patient populations.

Pharmacokinetics

Reported values in healthy adult subjects after single oral administration.

References

1. Hu, P, et al., & Dole, WP (2010). Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. Clinical drug investigation 30(4) 221–228. DOI:10.2165/11533050-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20192280

2. Khadzhynov, D, et al., & Peters, H (2012). Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis. Clinical pharmacokinetics 51(10) 661–669. DOI:10.1007/s40262-012-0003-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/23018529

3. Vaidyanathan, S, et al., & Camisasca, R (2006). Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. British journal of clinical pharmacology 62(6) 690–698. DOI:10.1111/j.1365-2125.2006.02696.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17118124

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)